脓毒症辅助治疗的新进展

doi:10.3969/j.issn.1002-1949.2016.04.007

Chinese Journal of Critical Care Medicine

2016, Vol. 36

Issue (4): 316-319 DOI: 10.3969/j.issn.1002-1949.2016.04.007

New development of the adjuvant treament for sepsis

ZHANG Jun-liang, ZENG Qi-yi, QIAN Xin-hua

Department of Neonatology, Southern Medical University Nanfang Hospital, Guangzhou 510515,China

Abstract
Figure/Table
References (33)
Related Citation (15)

[1] Dellinger RP, Levy MM, Rhodes A, et al. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012[J]. Crit Care Med, 2013,41（2）:580-637. [2] Martin GS, Mannino DM, Eaton S, et al. The epidemiology of sepsis in the United States from 1979 through 2000[J]. N Engl J Med,2003,348（16）:1546-1554. [3] Kabudula CW, Tollman S, Mee P, et al. Two decades of mortality change in rural northeast South Africa[J]. Global Health Action,2014,7:25596. [4] Levinson AT, Casserly BP, Levy MM. Reducing mortality in severe sepsis and septic shock[J]. Semin Respir Crit Care Med, 2011,32（2）:195-205. [5] 商娜,周荣斌.脓毒症流行病学研究[J].中国急救医学,2013，33（1）:8-12. [6] Angus DC, van der Poll T. Severe sepsis and septic shock[J]. N Engl J Med, 2013,369（9）:840-851. [7] 穆雪鹍, 傅应云, 韩雪梅, 等.脓毒症患者免疫失衡与疾病严重程度的关系[J].中国急救医学，2012，32（2）:120-123. [8] Boomer JS, To K, Chang KC, et al. Immunosuppression in patients who die of sepsis and multiple organ failure[J]. JAMA, 2011,306（23）:2594-2605. [9] 郭剑颖.脓毒症的免疫调理治疗[J].中国急救医学，2012,32（6）:546-549. [10] Minneci PC, Deans KJ, Banks SM, et al. Meta-analysis: the effect of steroids on survival and shock during sepsis depends on the dose[J]. Ann Intern Med, 2004,141（1）:47-56. [11] Leentjens J, Kox M, van der Hoeven JG, et al. Immunotherapy for the adjunctive treatment of sepsis: from immunosuppression to immunostimulation. Time for a paradigm change[J]. Am J Respir Crit Care Med, 2013, 187（12）:1287-1293. [12] Docke WD, Randow F, Syrbe U, et al. Monocyte deactivation in septic patients: restoration by IFN- gamma treatment[J]. Nat Med,1997,3（6）:678-681. [13] Bo L, Wang F, Zhu J, et al. Granulocyte-colony stimulating factor（G- CSF）and granulocyte- macrophage colony stimulating factor（GM-CSF）for sepsis: a meta-analysis[J]. Crit Care, 2011,15（1）:R58. [14] Bassir SH, Wisitrasameewong W, Raanan J, et al. Potential for stem cell- based periodontal therapy[J]. J Cell Physiol, 2016,231（1）:50-61. [15] Douglas JJ, Tsang JL, Walley KR. Sepsis and the innate- like response[J]. Intens Care Med, 2014, 40（2）:249-251. [16] Kjer-Nielsen L, Patel O, Corbett AJ, et al. MR1 presents microbial vitamin B metabolites to MAIT cells[J]. Nature, 2012,491（7426）:717-723. [17] Grimaldi D, Le Bourhis L, Sauneuf B, et al. Specific MAIT cell behaviour among innate- like T lymphocytes in critically ill patients with severe infections[J]. Intens Care Med, 2014,40（2）:192-201. [18] Wakao H, Yoshikiyo K, Koshimizu U, et al. Expansion of functional human mucosal-associated invariant T cells via reprogramming to pluripotency and redifferentiation[J]. Cell Stem Cell, 2013,12（5）:546-558. [19] Wannemuehler TJ, Manukyan MC, Brewster BD, et al. Advances in mesenchymal stem cell research in sepsis[J]. J Surg Res, 2012,173（1）:113-126. [20] Mei SHJ, Haitsma JJ, Dos Santos CC, et al. Mesenchymal stem cells reduce inflammation while enhancing bacterial clearance and improving survival in sepsis[J]. Am J Respir Crit Care Med, 2010,182（8）:1047-1057. [21] Krasnodembskaya A, Samarani G, Song YL, et al. Human mesen⁃chymal stem cells reduce mortality and bacteremia in gram-negative sepsis in mice in part by enhancing the phagocytic activity of blood monocytes[J]. Am J Physiol-Lung C, 2012,302（10）:L1003-L1013. [22] Kimbrel EA, Kouris NA, Yavanian GJ, et al. Mesenchymal stem cell population derived from human pluripotent stem cells displays potent immunomodulatory and therapeutic properties[J]. Stem Cells Dev, 2014,23（14）:1611-1624. [23] Spite M, Norling LV, Summers L, et al. Resolvin D2 is a potent regulator of leukocytes and controls microbial sepsis[J]. Nature,2009,461（7268）:1287-U125. [24] Ueda T, Fukunaga K, Seki H, et al. Combination therapy of 15-epilipoxin A4 with antibiotics protects mice from Escherichia coli-induced sepsis[J]. Crit Care Med, 2014,42（4）:e288-95. [25] Gong J, Guo S, Li HB, et al. BML-111, a lipoxin receptor agonist,protects haemorrhagic shock- induced acute lung injury in rats[J].Resuscitation, 2012,83（7）:907-912. [26] Li H, Wu Z, Feng D, et al. BML-111, a lipoxin receptor agonist, attenuates ventilator-induced lung injury in rats[J]. Shock, 2014,41（4）:311-316. [27] Jones AE, Puskarich MA. The Surviving Sepsis Campaign guidelines 2012: update for emergency physicians[J]. Ann Emerg Med,2014,63（1）:35-47. [28] Lemarie J, Blet A, Bouazza Y, et al. Dexamethasone and recombinant human activated protein C improve myocardial function and efficiency during experimental septic shock[J]. Shock, 2014,41（6）:522-527. [29] Bernard GR, Vincent JL, Laterre PF, et al. Efficacy and safety of recombinant human activated protein C for severe sepsis[J]. N Engl J Med, 2001,344（10）:699-709. [30] Abraham E, Laterre PF, Garg R, et al. Drotrecogin alfa（activated）for adults with severe sepsis and a low risk of death[J]. N Engl J Med, 2005,353（13）:1332-1341. [31] Nadel S, Goldstein B, Williams MD, et al. Drotrecogin alfa（activated）in children with severe sepsis: a multicentre phase Ⅲ randomised controlled trial[J]. Lancet, 2007,369（9564）:836-843. [32] Ranieri VM, Thompson BT, Barie PS, et al. Drotrecogin alfa（activated）in adults with septic shock[J]. N Engl J Med, 2012,366（22）:2055-2064. [33] Opal SM, Dellinger RP, Vincent JL, et al. The next generation of sepsis clinical trial designs: what is next after the demise of recombinant human activated protein C[J]. Crit Care Med, 2014,42（7）:1714-1721.